SCHEMBL2155354

SCHEMBL2155354

CCCCCC#CC=CS(=O)(=O)N1CCN(c2cccc(OC)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.46
MAPT P10636 4/20 0.44
KCNH2 Q12809 2/20 0.44
GAA P10253 1/20 0.43
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
HTR7 P34969 1/20 0.41
GRM2 Q14416 1/20 0.41
KMT2A Q03164 2/20 0.41
THRB P10828 1/20 0.41
LMNA P02545 1/20 0.40
NPC1 O15118 1/20 0.40
MEN1 O00255 1/20 0.39
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155349 1.00 DRD2 (0.46) DRD2MAPTKCNH2GAATP53
SCHEMBL2156078 0.89 MAPT (0.54) DRD2MAPTGAATP53SMN1; SMN2
SCHEMBL2156082 0.89 MAPT (0.54) DRD2MAPTGAATP53SMN1; SMN2
SCHEMBL2154808 0.88 SMN1; SMN2 (0.54) MAPTKCNH2SMN1; SMN2KMT2AMEN1
SCHEMBL2154810 0.88 SMN1; SMN2 (0.54) MAPTKCNH2SMN1; SMN2KMT2AMEN1
SCHEMBL2155851 0.86 TSHR (0.51) DRD2MAPTGAASMN1; SMN2KMT2A
SCHEMBL2155846 0.86 TSHR (0.51) DRD2MAPTGAASMN1; SMN2KMT2A
SCHEMBL2155103 0.86 PKM (0.41) MAPTGAASMN1; SMN2HTR7KMT2A
SCHEMBL2155105 0.86 PKM (0.41) MAPTGAASMN1; SMN2HTR7KMT2A
SCHEMBL16493653 0.84 DRD2 (0.46) DRD2MAPTKCNH2TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP claimed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US claimed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US claimed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 CN claimed
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP disclosed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS DRD2 4576/4885MAPT 4423/4885KCNH2 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.